Search
Close this search box.
Search
Subscriber Log In

2023 in Digital Health: Four Trends Driving Transformation

Medicine-doctor-touching-electronic-medical-record-on-tablet-DNA

2023 is a year that many in the pharma market will be happy to see the back of, and the digital health ecosystem is no exception. Some of this can be attributed to the growing pains of a young-ish market and some to the macroeconomic climate resulting in a scarcity of funding. Whatever the causes, […]

In Case You Missed It: Three Things We Learned in Our 2024 Preview Webinar

evaluate-featured-image

Our focus was on the 2024 Preview, our annual report that looks at the top drugs, companies, potential launches and much more for the year ahead. In the webinar, our team talked through some of the highlights and discussed some of the stories behind the data, with a view to what it means for pharma […]

Sneak Peek at Our 2024 Preview Webinar

evaluate-featured-image

Fortunately, the annual Preview report that we publish at Evaluate is based on our consensus forecasting data. While that doesn’t guarantee accuracy – in the current market, guarantees are hard to come by – it does mean that the insight we share is based on some pretty solid data. The 2024 Preview report was published […]

Competitive Intelligence and the Quest for the Single Source of Truth

evaluate-featured-image

What’s in your competitor’s pipeline? How are their trials progressing? Who is on the cusp of a merger that will increase their funding and how will this impact your business? Continuous monitoring of the market landscape is the bread and butter of a CI professional and you can’t afford to miss anything that may impact […]

2024 Preview: Are We There Yet?

are-we-there-yet-sign-featured-image

After a year in which investor sentiment went from bad to worse, 2024 has started on a more positive note. Last week’s JP Morgan conference saw a flurry of partnership and acquisition announcements, building on the last couple of weeks of December which saw 2023’s deal making end with a bang. If the end is […]

Revolutionising Pharma: Unveiling the Role of Digital Health in Biopharma Giants

evaluate-featured-image

While the rewards for successfully developing a new therapy can be measured in billions, the R&D costs and the risk are also sky-high. It’s hardly surprising, then, that efficiency is one of the key targets for many of the digital health and AI tools in the pharma sphere. It also, therefore, makes sense that it’s […]

In Case You Missed It: Three Things We Learned in Our CDMO Webinar

handshake-partnership-featured-image

If you missed it, the recording is available here. If you’re short on time, here are three of the key points that I took away from the session. Our speakers included Amanda Micklus from the Norstella consulting team, and Vince Spurr, one of our CDMO experts. Perhaps more importantly, we were joined by Matt Hewitt […]

In Sickness and in Health: The CDMO/Pharma Relationship

man-wearing-ring-womans-hand-engagement-ring

There are two inflection points where a pharma or biotech company looks to a CDMO. In one instance, it’s a technology transfer to create regional or incremental capacity, helping reduce the risk of a single-source manufacturing process. While this isn’t risk-free, it’s relatively straightforward. In recent years, though, we’ve seen an increase in companies seeking […]

Themes from BIO Europe

Team-Photo

There’s far too much to share in one blog post, but there were three areas that I wanted to summarise as I think they’re a good indicator of the current state of the biopharma market and give us an insight into what we can expect from pharma and biotech in 2024. 1. Dealmaking Increasing competition […]